Info banner
A significant part of the Healthesystems vision is to create a more integrated experience for our customers
Info banner
A significant part of the Healthesystems vision is to create a more integrated experience for our customers

Transforming the workers’ compensation pharmacy and ancillary benefits management experience

Powered by state-of-the-art technology
Supported by human-centered service
Informed by industry expertise
Inspired by a commitment to care
women with a migraine post image
blog

Novel Migraine Agents: What is Their Place in Injured Worker Therapy?

While these drugs offer relief for migraine sufferers, what are the efficacy and cost considerations for injured workers?
Read More
rxinformer

Ask a Clinician: What Do I need to Know About DME Trends?

Healthesystems clinicians tackle questions about Durable Medical Equipment (DME).
Read More
MAC Monitor and magazine cover graphic
INDUSTRY SURVEY

2024 Industry Survey Report

This sixth annual survey report highlights the top challenges and priorities of 500 industry professionals.
Read More

Featured Videos

Personalize my experience

Make selections below to see articles and information related to your role and interests.
  • I am a

  • I'm interested in

Tanezumab Trials Yield Positive Results for Pain Management

Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.

Mar 2019

Opioid Imbalance: Risk Disparities Among Diverse Patient Populations

Demographic factors such as gender, ethnicity, socioeconomic status, age, and location can impact opioid risks.

Mar 2019

Tackling Topicals: Clinicians Takes Notice

Despite having little clinical impact, topical creams continue to be utilized widely in workers’ comp.

Mar 2019

The Drug Price Debate

Federal lawmakers and administrative agencies continue to investigate how to best lower ever-increasing drug prices.

Mar 2019

FDA Establishes Guidance for Brain-Computer Interface Technologies

Can special implants in the brain override paralysis? The FDA believes one day they could.

Mar 2019

FDA Nudges Developers to Create Over-the-Counter Naloxone

The FDA created special drug labels to clear a development hurdle and encourage manufacturers.

Feb 2019

Marijuana – What to Expect in 2019 and Beyond

Dr. Robert Goldberg and Sandy Shtab talk with Risk & Insurance about changing attitudes and policies around medical marijuana, its potential role in reducing reliance on opioids, and what this can mean for payers, employers, patients and PBMs.

Feb 2019

Troubling Trends for Benzodiazepines

Prescribing has doubled since 2003, overdose deaths quadrupled since 1996, and misuse accounts for 20% of benzodiazepine use.

Feb 2019

PTSD Coverage: More States Draft Legislation

Kentucky, Connecticut, Idaho, and West Virginia proposed bills to make PTSD compensable for first responders.

Feb 2019


Opioid Marketing Tied to Higher Prescribing and Overdose

A new JAMA study finds that increased county-level opioid marketing was tied to elevated overdose mortality.

Feb 2019

FDA Approves Two New Strengths of Apadaz

The opioid prodrug for acute pain will soon be available in both a stronger and weaker dose.

Jan 2019

What’s Ahead for 2019 Workers’ Comp Regulations

As 2018’s legislative trends continue to spill into 2019, what big initiatives might impact workers’ comp this year?

Jan 2019

JAMA Examines Association of Early Physical Therapy with Long-Term Opioid Use

An analysis of 90,000 private claims explores the relationship between early PT and reduced long-term opioid use in musculoskeletal pain.

Jan 2019

The Legality of Self-Referrals

Can doctors in certain states refer patients to pharmacies which they partially own?

Jan 2019

The Buzz Behind Digital Therapeutics

Will doctors one day prescribe apps meant to drive behavior changes instead of drugs?

Jan 2019

FDA Approves First Prescription App for Opioid Use Disorder

The reSET-O app uses cognitive behavioral therapy techniques to assist patients engaged in medication-assisted therapy for opioid dependence.

Dec 2018

Hero’s Welcome: Growing PTSD Coverage for First Responders

Formulary and claims management considerations for populations at risk for “mental-only” cases of PTSD.

Dec 2018

New Guidelines for Opioid-Induced Constipation

The American Gastroenterological Association released guidance on properly prescribing medications for OIC.

Dec 2018

Marijuana Use Rising Among Older Populations

Marijuana use among adults aged 50-64 tripled from 2002-2014.

Dec 2018

In Case You Missed It: 5 Takeaways on Value-Based Models in Work Comp

Dr. Silvia Sacalis of Healthesystems teamed up with Dr. Adam Seidner of The Hartford for a session at NWCDC – here are 5 key takeaways.

Dec 2018

By the Numbers

A collection of workers’ compensation facts and figures

Winter 2018/2019

State of the States

A roundup of regulatory activity around the country

Winter 2018/2019

Myth Busters: Medical Marijuana Edition

Our clinicians answer common questions from claims professionals

Winter 2018/2019

Perspectives: Status Woe - Outdated Regulation Impedes Healthcare Innovation

Industry thought leaders share their insights

Winter 2018/2019

Shifting Gears in Patient Transportation with Rideshare

How rideshare models like Lyft and Uber can reduce costs and improve patient experience

Winter 2018/2019

Patient Engagement Is Personal: How to Help Injured Workers Help Themselves

Strategies for increasing patient engagement in recovery and associated outcomes

Winter 2018/2019

Opioid Imbalance: Risk Disparities Among Diverse Patient Populations

Population-based opioid risks include gender, socioeconomic status, and ethnicity

Winter 2018/2019

The Opioids Crisis: Our Defining Moment

Special commentary on the opioid crisis from our clinical leaders

Winter 2018/2019

Hero's Welcome: Growing PTSD Coverage for First Responders

Formulary and claims management considerations for populations at risk for PTSD

Winter 2018/2019

FDA Approves New Opioid, Dsuvia

Five-to-ten times stronger than fentanyl, this drug is not for consumer use, and many claim it could worsen the opioid crisis.

Nov 2018

1 2 3 4 5 16 17 18 19 20 21
lockenvelopephone-handsetmagnifiermenuarrow-rightcross-circle